North Chicago, Illinois, U.S., September 29, 2026
AbbVie has entered into a new partnership with Valkai to deploy advanced artificial intelligence (AI) capabilities across targeted areas of clinical development, strengthening the pharmaceutical company’s efforts to integrate AI throughout the drug development process. The collaboration will introduce purpose-built AI capabilities designed to improve efficiency in clinical research, help teams generate insights more quickly and support opportunities to reduce development timelines. As clinical data becomes increasingly complex and voluminous, AbbVie said the partnership will help its teams use AI alongside human scientific expertise to support decision-making and accelerate the development of medicines for patients.
AbbVie Expands AI Across Clinical Research
Through the collaboration, AbbVie will deploy Valkai’s life sciences AI platform in selected areas of clinical development. The technology is intended to help clinical research teams work more efficiently, analyze growing volumes of information and identify insights that can support scientific and clinical decisions. AbbVie said AI is already an important component of its broader research and development strategy, and the partnership with Valkai will help expand those capabilities across clinical development. The company is pursuing AI applications across its organization to strengthen scientific innovation, connected operations and the way medicines are discovered, developed and delivered. The partnership comes as pharmaceutical companies increasingly explore AI to manage the growing complexity of clinical data and drug development workflows. AbbVie said its approach is focused on using AI to complement employee expertise rather than replace scientific judgment. According to the company, combining advanced AI capabilities with human expertise can allow teams to spend more time on important scientific decisions while reducing time devoted to manual processes. The collaboration therefore reflects a broader shift toward data-driven clinical development, where computational technologies are increasingly being incorporated into pharmaceutical research and development operations.
Valkai Technology Supports Faster Clinical Insights
Valkai describes itself as an AI operating system for life sciences, designed to help organizations make faster and smarter decisions throughout drug development. Under the AbbVie collaboration, Valkai’s capabilities will be applied specifically to selected areas of clinical development, with the goal of improving research efficiency and accelerating the generation of useful insights. AbbVie Vice President of Clinical Sciences Andrew Campbell said AI capabilities such as Valkai’s platform have the potential to reduce the time spent on manual processes and allow clinical teams to focus more attention on scientific interpretation and clinical strategy. AbbVie Chief Business and Strategy Officer Nicholas Donoghoe said the partnership reflects the company’s focus on applying AI where it can create meaningful impact for the business and patients. The company said that as clinical information continues to increase in both volume and complexity, AI can help teams generate insights more rapidly and concentrate on decisions that have the greatest scientific importance. Valkai CEO and co-founder Vignesh Rajendran said the partnership combines the company’s AI capabilities with AbbVie’s scientific expertise and scale.
Advertisement
AI@AbbVie Strengthens Drug Development Strategy
The collaboration with Valkai forms part of AI@AbbVie, the company’s enterprise-wide approach to using artificial intelligence to advance scientific innovation, strengthen business outcomes and improve how medicines are discovered, developed and delivered. AbbVie said AI is being used as an enabler across research and development, operations and other business functions, with human expertise and responsible governance remaining central to its implementation strategy. The company aims to use AI to enhance productivity, strengthen decision-making and accelerate progress across its pharmaceutical development activities.
For the pharmaceutical industry, the AbbVie-Valkai partnership highlights the growing role of AI in clinical development, particularly as researchers manage increasingly sophisticated datasets and complex development programs. Rather than announcing a specific new medicine or clinical-trial outcome, the collaboration focuses on the underlying technology infrastructure that can support pharmaceutical research. The initiative demonstrates how established drug developers are incorporating specialized life-sciences AI platforms into clinical workflows to improve efficiency, generate insights and potentially support faster progression of medicines through development.
Source: AbbVie press release
